1. Defining B2B SaaS: models, segments, and 2026 benchmarks
B2B SaaS organizes in several sub-models with distinct expected metrics.
B2B SaaS groups three main sub-models. Horizontal SaaS (productivity, communication, CRM) targets all industries — European examples: Spendesk, PayFit, Aircall, Pleo. Huge market (TAM €100B+ globally) but intense competition with dominant US players (Salesforce, Slack, HubSpot). Average acquisition cycles, moderate churn (1.5-3%/month). Vertical SaaS (industry-specific: health, legal, HR, finance, real estate) — examples: Doctolib (health), Lemonway (payment), Talentia (HR), Yousign (legal). Smaller market but higher entry barriers and lower churn (0.5-1.5%/month).
Third sub-model is data/AI infrastructure SaaS, more technical: APIs, data platforms, dev tools — examples Algolia, Datadog, Snowflake. Higher fundraise tickets (Seed €3-5M, Series A €10-20M) due to R&D needs. Very high gross margins (80-90%) compensating long acquisition cycles. 2024 benchmarks (SaaStr, OpenView) show contrasting market state: B2B SaaS top quartile startups maintain 100-150% YoY growth with churn < 1%/month; bottom quartile startups struggle at 30-50% growth with churn 3-5%/month.
Expected metrics vary by stage. For Seed (€1-2M fundraise), 2024 benchmarks: MRR €30-50k/month, MoM growth 15-25%, gross churn < 3%/month, NDR (Net Dollar Retention) > 100%, LTV/CAC > 3:1 from 6-month cohort, payback < 18 months. For Series A (€5-10M fundraise), benchmarks: ARR €1-3M/year, YoY growth 100-150%, churn < 2%/month (ideally < 1% for vertical), NDR > 110%, LTV/CAC > 3:1, payback < 12 months, magic number > 0.75.
Benchmark evolution 2022→2024
B2B SaaS benchmarks have tightened between 2022 (market peak) and 2024 (post-bubble correction). Growth vs efficiency ratio (Rule of 40: growth % + margin %) remains reference, but with re-focus on efficiency. A startup at 60% growth and 20% loss (Rule of 40 = 40) remains fundable; but 100% growth and 80% loss (Rule of 40 = 20) becomes difficult. Rule of 40 calculation is now standard in Series A BPs.